Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Rociletinib (CNX-419) 是一种可口服的EGFR 抑制剂,能够抑制 EGFRL858R/T790M 和 EGFRWT 的活性,IC50值分别为 21.5 nM 和 303.3 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 415 | 现货 | ||
10 mg | ¥ 679 | 现货 | ||
50 mg | ¥ 1,246 | 现货 | ||
100 mg | ¥ 1,997 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 498 | 现货 |
产品描述 | Rociletinib (CNX-419) is an orally available small molecule, irreversible inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity. |
靶点活性 | EGFR (WT):303.3 nM(Ki), EGFR (L858R/T790M):21.5 nM(Ki) |
体外活性 | CO-1686在所有EGFR突变体模型以及表达EGFRL858R-和EGFRL858R/T790M的转基因小鼠中引起显著的剂量依赖性肿瘤生长抑制. |
体内活性 | CO-1686选择性抑制NSCLC细胞表达的突变体EGFR的生长,GI50范围为7 到 32 nM,并诱导细胞凋亡。耐CO-1686的NSCLC细胞系表现出上皮 - 间充质转变的迹象并且对AKT抑制剂的敏感性增加。CO-1686在表达突变型EGFR的细胞中抑制p-EGFR,其IC50范围为62至187 nM,同时在三种WT EGFR表达细胞中抑制EGFR磷酸化,IC50> 2,000 nM。 |
激酶实验 | Inhibition Kinetics Studies: Recombinant human wild-type and T790M/L858R double mutant EGFR, both Nterminal GST-tagged, are used in the assay. The Omnia continuous read assay is performed as described by the vendor. |
细胞实验 | Cells are seeded at 3,000 cells per well in growth media supplemented with 5% FBS, 2 mmol/L, L-glutamine, and 1% penicillin–streptomycin, allowed to adhere overnight, and treated with a dilution series of test compounds for 72 hours. Cell viability is determined by CellTiter-Glo, and results are represented as background-subtracted relative light units normalized to a dimethyl sulfoxide (DMSO)–treated control. Growth inhibition (GI 50) values are determined by GraphPad Prism 5.04. MK-2206 and XL-880 compounds are obtained from Selleck Chemical. CI data are generated using CalcuSyn.(Only for Reference) |
别名 | AVL-301, CNX-419, CO-1686 |
分子量 | 555.55 |
分子式 | C27H28F3N7O3 |
CAS No. | 1374640-70-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 93 mg/mL (167.4 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.8 mL | 9.0001 mL | 18.0002 mL | 45.0005 mL |
5 mM | 0.36 mL | 1.8 mL | 3.6 mL | 9.0001 mL | |
10 mM | 0.18 mL | 0.9 mL | 1.8 mL | 4.5 mL | |
20 mM | 0.09 mL | 0.45 mL | 0.9 mL | 2.25 mL | |
50 mM | 0.036 mL | 0.18 mL | 0.36 mL | 0.9 mL | |
100 mM | 0.018 mL | 0.09 mL | 0.18 mL | 0.45 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Rociletinib 1374640-70-6 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR CNX 419 AVL 301 HER1 Inhibitor inhibit AVL-301 CO 1686 CNX-419 ErbB-1 AVL301 CO-1686 CNX419 Epidermal growth factor receptor CO1686 inhibitor